Difference between revisions of "Malignant melanoma"

Jump to navigation Jump to search
Line 225: Line 225:


It is suggested that one should:
It is suggested that one should:
*Tease try to apart melanoma cells from benign melanocytes.
#Tease try to apart melanoma cells from benign melanocytes.
*Report the clearance of the nearest melanoma cell to the margin.
#*Melanocytes with nuclear atypia = melanoma cells.
**Positive margins are when a melanoma cell is inked.
#Report the clearance of the nearest melanoma cell to the margin.
*Use [[immunostain]]s to assist the assessment of difficult cases.<ref name=pmid21797920>{{Cite journal  | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref>
#*Positive margins are when a melanoma cell is touching ink.
**MiTF is considered the preferred marker.
#Use [[immunostain]]s to assist the assessment of difficult cases.<ref name=pmid21797920>{{Cite journal  | last1 = Kim | first1 = J. | last2 = Taube | first2 = JM. | last3 = McCalmont | first3 = TH. | last4 = Glusac | first4 = EJ. | title = Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. | journal = J Cutan Pathol | volume = 38 | issue = 10 | pages = 775-9 | month = Oct | year = 2011 | doi = 10.1111/j.1600-0560.2011.01763.x | PMID = 21797920 }}</ref>
**MART-1 (Melan A) is considered to overestimate melanocytes.
#*MiTF is considered the preferred marker.
#*MART-1 (Melan A) is considered to overestimate melanocytes.


====Subtypes====
====Subtypes====
48,830

edits

Navigation menu